Heghine Khachatryan: Toward Personalized Management of Glanzmann Thrombasthenia
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Journal of Thrombosis and Haemostasis (JTH)’s post on LinkedIn, adding:
“The development of antiplatelet antibodies in Glanzmann thrombasthenia remains one of the most clinically significant challenges in the long-term management of this rare inherited platelet disorder.
Beyond increasing the risk of platelet transfusion refractoriness, alloimmunization substantially complicates perioperative care and the treatment of life-threatening bleeding episodes.
Natural history data from large multicenter cohorts are therefore invaluable for identifying patients at greatest risk, optimizing transfusion strategies, and informing individualized therapeutic approaches, including the early integration of recombinant activated factor VII and emerging non-transfusion-based therapies.
This study represents an important contribution toward a more evidence-based and personalized management paradigm for patients with Glanzmann thrombasthenia.”
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Dominique Desprez et al., adding:
“Natural history of antiplatelet antibody formation in patients with Glanzmann thrombasthenia: a French multicenter prospective study
In 55 GT patients, anti-αIIbβ3 antibodies developed in 36%—mostly transient and genotype-linked—reducing fibrinogen binding but not triggering platelet damage, underscoring the value of antibody monitoring.”
Title: Natural history of antiplatelet antibody formation in patients with Glanzmann thrombasthenia: a French multicenter prospective study
Authors: Dominique Desprez, Roseline d’Oiron, Sophie Voisin, Céline Falaise, Marie-Christine Alessi, Paul Saultier, Géraldine Lavigne, Arnaud Essaydi, Marie-Joelle Apithy, Arnaud Dupuis, Valérie Goin, Yoann Huguenin, Mathieu Fiore
Other posts featuring Heghine Khachatryan and Journal of Thrombosis and Haemostasis on Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention